Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $310.61M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.38M
Average 1.73M
Returns on capital
Larimar Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-212.2%
avg 240.7%
ROIC
-210.0%
avg 294.2%
ROA
-113.6%
avg -86.6%
Analysis
ROA is currently the strongest return metric at -113.6% versus its period average of -86.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Carole S. Ben-Maimon | CEO & Director | USD 976.4K | 67 | — | — |
Michael Celano | Secretary & Chief Financial Officer | USD 697K | 67 | 234.25K | 0.27% |
Gopi Shankar | Chief Development Officer | USD 642.35K | 55 | 81.44K | 0.10% |
Russell G. Clayton | Chief Medical Officer | — | 65 | — | — |
Francis Michael Conway | Vice President & Controller | — | — | — | — |
John Berman | Vice President of Finance & Administration | — | — | — | — |
John Harlow Jr. | President & COO | — | 50 | — | — |
Jennifer Spokes Johansson | Vice President of Legal & Compliance | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
15
$26.10M
Sells
0
$0.00
Net Transaction Value
+$26.10M
Net buying
Most Active
Flynn James E
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 12, 26Nov 12, 2026 | Hamilton Thomas Edward Indirect | Buy | $187.1K$187,082.00 |
| Nov 11, 26Nov 11, 2026 | BEN-MAIMON CAROLE Direct | Buy | $50K$49,953.38 |
| Nov 11, 26Nov 11, 2026 | THOMAS FRANK E Direct | Buy | $21.8K$21,800.00 |
| Nov 11, 26Nov 11, 2026 | Truitt Joseph Direct | Buy | $9.8K$9,791.60 |
| Nov 11, 26Nov 11, 2026 | Harlow John B. Jr. Direct | Buy | $49.9K$49,918.32 |
| Nov 11, 26Nov 11, 2026 | Celano Michael Direct | Buy | $50K$49,991.53 |
| Nov 11, 26Nov 11, 2026 | Shankar Gopi Direct | Buy | $13.5K$13,549.00 |
| Jul 6, 26Jul 6, 2026 | Hamilton Thomas Edward Direct | Buy | $166.9K$166,890.00 |
| Feb 27, 26Feb 27, 2026 | Flynn James E Indirect | Buy | $5.4M$5,420,060.00 |
| Feb 27, 26Feb 27, 2026 | Flynn James E Indirect | Buy | $5.4M$5,420,050.00 |
1–10 of 15
Summary
Insiders reported 15 buys worth $26.10M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $26.10M. Flynn James E was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Larimar Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about LRMR's management, answered from reported figures.
Who manages LRMR?
Larimar Therapeutics, Inc. (LRMR) lists 8 active executives. The top listed executive is Carole S. Ben-Maimon, CEO & Director.
Are LRMR insiders buying or selling?
Recent insider activity shows net buying of $192.35M.
Continue the stock analysis
Jump to another research area for this company.